Drug Profile
Research programme: microbiome-targeted therapeutics - Kaleido Biosciences
Alternative Names: Microbiome Metabolic Therapies (MMT™) - Kaleido BiosciencesLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Kaleido Biosciences
- Class Anti-infectives; Antineoplastics; Cardiovascular therapies; Hepatoprotectants; Polysaccharides; Urologics
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Immunological disorders; Liver disorders
- No development reported Metabolic disorders
- Discontinued Cardiovascular disorders; Renal failure
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Metabolic-disorders in USA (PO)
- 01 Nov 2021 Kaleido Biosciences plans to file Investigational New Drug (IND) or regulatory equivalent outside the USA
- 01 Nov 2021 Kaleido Biosciences plans clinical trials for microbiome targeted therapeutics in USA and outside the USA